Logo image of GBIO

GENERATION BIO CO (GBIO) Stock Fundamental Analysis

NASDAQ:GBIO - Nasdaq - US37148K1007 - Common Stock - Currency: USD

0.6102  0 (-0.78%)

After market: 0.6096 0 (-0.1%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to GBIO. GBIO was compared to 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for GBIO as it has an excellent financial health rating, but there are worries on the profitability. GBIO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GBIO had negative earnings in the past year.
In the past year GBIO has reported a negative cash flow from operations.
In the past 5 years GBIO always reported negative net income.
GBIO had a negative operating cash flow in each of the past 5 years.
GBIO Yearly Net Income VS EBIT VS OCF VS FCFGBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -58.47%, GBIO is in line with its industry, outperforming 42.81% of the companies in the same industry.
GBIO has a Return On Equity of -139.28%. This is in the lower half of the industry: GBIO underperforms 63.23% of its industry peers.
Industry RankSector Rank
ROA -58.47%
ROE -139.28%
ROIC N/A
ROA(3y)-31.7%
ROA(5y)-53.62%
ROE(3y)-47.3%
ROE(5y)-106.53%
ROIC(3y)N/A
ROIC(5y)N/A
GBIO Yearly ROA, ROE, ROICGBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GBIO Yearly Profit, Operating, Gross MarginsGBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -20K -40K -60K -80K

More info and screens

7

2. Health

2.1 Basic Checks

GBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GBIO has more shares outstanding
The number of shares outstanding for GBIO has been increased compared to 5 years ago.
There is no outstanding debt for GBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GBIO Yearly Shares OutstandingGBIO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M
GBIO Yearly Total Debt VS Total AssetsGBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

GBIO has an Altman-Z score of -4.11. This is a bad value and indicates that GBIO is not financially healthy and even has some risk of bankruptcy.
GBIO has a Altman-Z score (-4.11) which is in line with its industry peers.
GBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.11
ROIC/WACCN/A
WACC9.52%
GBIO Yearly LT Debt VS Equity VS FCFGBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

GBIO has a Current Ratio of 6.34. This indicates that GBIO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.34, GBIO is in the better half of the industry, outperforming 63.59% of the companies in the same industry.
A Quick Ratio of 6.34 indicates that GBIO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.34, GBIO is in the better half of the industry, outperforming 63.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.34
Quick Ratio 6.34
GBIO Yearly Current Assets VS Current LiabilitesGBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for GBIO have decreased strongly by -10.61% in the last year.
GBIO shows a strong growth in Revenue. In the last year, the Revenue has grown by 513.27%.
The Revenue has been growing by 171.53% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-10.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.51%
Revenue 1Y (TTM)513.27%
Revenue growth 3YN/A
Revenue growth 5Y171.53%
Sales Q2Q%252%

3.2 Future

The Earnings Per Share is expected to grow by 9.99% on average over the next years. This is quite good.
Based on estimates for the next years, GBIO will show a very strong growth in Revenue. The Revenue will grow by 23.96% on average per year.
EPS Next Y4.39%
EPS Next 2Y20%
EPS Next 3Y14.5%
EPS Next 5Y9.99%
Revenue Next Year370.54%
Revenue Next 2Y35.82%
Revenue Next 3Y26.61%
Revenue Next 5Y23.96%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GBIO Yearly Revenue VS EstimatesGBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
GBIO Yearly EPS VS EstimatesGBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GBIO Price Earnings VS Forward Price EarningsGBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GBIO Per share dataGBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

GBIO's earnings are expected to grow with 14.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20%
EPS Next 3Y14.5%

More info and screens

0

5. Dividend

5.1 Amount

GBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENERATION BIO CO

NASDAQ:GBIO (2/21/2025, 8:23:03 PM)

After market: 0.6096 0 (-0.1%)

0.6102

0 (-0.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)05-12 2025-05-12/amc
Inst Owners84.39%
Inst Owner Change-2.71%
Ins Owners2.44%
Ins Owner Change1.16%
Market Cap40.76M
Analysts80
Price Target7.14 (1070.11%)
Short Float %4.05%
Short Ratio4.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.52%
Min EPS beat(2)-9.16%
Max EPS beat(2)20.2%
EPS beat(4)1
Avg EPS beat(4)-43.46%
Min EPS beat(4)-169.03%
Max EPS beat(4)20.2%
EPS beat(8)4
Avg EPS beat(8)-19.39%
EPS beat(12)6
Avg EPS beat(12)-11.93%
EPS beat(16)8
Avg EPS beat(16)-6.88%
Revenue beat(2)2
Avg Revenue beat(2)199.05%
Min Revenue beat(2)104.65%
Max Revenue beat(2)293.44%
Revenue beat(4)4
Avg Revenue beat(4)183.37%
Min Revenue beat(4)104.65%
Max Revenue beat(4)293.44%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.67%
EPS NQ rev (1m)0.94%
EPS NQ rev (3m)4.09%
EPS NY rev (1m)0.16%
EPS NY rev (3m)1%
Revenue NQ rev (1m)31.58%
Revenue NQ rev (3m)31.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)8.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.19
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 0.39
EV/EBITDA N/A
EPS(TTM)-2.19
EYN/A
EPS(NY)-1.1
Fwd EYN/A
FCF(TTM)-1.56
FCFYN/A
OCF(TTM)-1.46
OCFYN/A
SpS0.28
BVpS1.56
TBVpS1.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.47%
ROE -139.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.7%
ROA(5y)-53.62%
ROE(3y)-47.3%
ROE(5y)-106.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 129.97%
Cap/Sales 35.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.34
Quick Ratio 6.34
Altman-Z -4.11
F-Score4
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)147.89%
Cap/Depr(5y)335.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.51%
EPS Next Y4.39%
EPS Next 2Y20%
EPS Next 3Y14.5%
EPS Next 5Y9.99%
Revenue 1Y (TTM)513.27%
Revenue growth 3YN/A
Revenue growth 5Y171.53%
Sales Q2Q%252%
Revenue Next Year370.54%
Revenue Next 2Y35.82%
Revenue Next 3Y26.61%
Revenue Next 5Y23.96%
EBIT growth 1Y27.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.47%
EBIT Next 3Y10.49%
EBIT Next 5YN/A
FCF growth 1Y6.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.49%
OCF growth 3YN/A
OCF growth 5YN/A